Time for Action: Investing in Health Canada
Recent data reveal a troubling trend: Health Canada is taking longer to assess generic and biosimilar drug submissions, delaying the arrival of cost-saving prescription medications on the market, and increasing costs for Canadian taxpayers and patients.
The number and complexity of drug submissions received by Health Canada have been increasing for many years, but resources for its drug review programs have remained largely static and chronically underfunded.
Regulators in other countries have seen similar submission trends and made the strategic hiring investments needed to meet increased demands and maintain predictable business operations.
As the federal government prepares to unveil its budget on November 4, it is vital that it address these delays through strategic investments in Health Canada’s resources and staffing.
The issue is pressing.
Author's summary: Canada needs investments in Health Canada.
More News
- Charlie Kirk’s accused killer allowed to wear street clothes in court
- Telcos and ISPs: The time to prioritise cyber security is now
- Nokia commits to full AI-RAN GPU play on new Nvidia RAN compute platform - The Mobile Network
- Nicole Kidman thriving while Keith Urban struggles after split
- Myrio Therapeutics Announces Collaboration with Leading Research Institutions to Advance Solid Tumor T cell Immunotherapeutics - FNArena.com
- Al Nassr Al-Ittihad Jeddah 28 10 2025 Live Score and Match Summary
- Fiddler Scott Woods doesn't dip his bow into politics
- Scott Woods band returning for Christmas Hoedown | DrumhellerMail
- Everything to know about Toronto’s Budweiser Stage being renamed and what’s to come
- From WNBA Court To Playmate Glam: Check Out Kysre Gondrezick’s Sexiest Photos